Results
Trial of Citalopram for the Prevention of Depression
Learn MoreResults
A Pharmacokinetic Assessment of Intermittent Rifabutin Dosing Regimens in the Setting of Protease Inhibitor Therapy with a Combination of Ritonavir and Saquinavir in HIV-Infected Patients: Trial results
Learn MoreResults
A Multicentre, Randomized, Double-Blind, Phase II Study to Evaluate the Safety, Tolerance and Efficacy of Multiple Doses of SCH 56592 versus Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients: Trial results
Learn MoreResults
A Phase III Controlled, Double-Blind, Randomized, Multinational Study for the Preventative Therapy of Latent Tuberculosis in HIV-positive Individuals: Isoniazid (300 mg/day x 12 months ) vs. Rifabutin (300 mg/day x 3 months)
Learn MoreResults
A Randomized Trial of the Use of N-acetylcysteine for the Prevention of Sulphonamide Hypersensitivity Reactions When Used for the Prevention of Pneumocystis Carinii Pneumonia in Patients with HIV infection: Trial results
Learn MoreResults
Evaluation of SQ32,756 (BV ara U) Versus Acyclovir in the Treatment of Localized Herpes Zoster in HIV Infected Patients
Learn MoreOngoing
Association of vitamin D insufficiency with non-alcoholic fatty liver disease in HIV mono-infected patients
Learn MoreResults
Anemia Among HIV-infected Children Receiving Zidovudine: Identification of Markers of Erythropoietin Deficiency and Likelihood of Response to Exogenous Erythropoietin
Learn MoreResults
Rifabutin Therapy for the Prevention of MAC in Patients with AIDS
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
